Therefore, only cabozantinib and vandetanib are approved by the FDA to treat locally advanced or metastatic MTC or NSCLC patients with RET and allow researchers to find more effective agents, such as selective inhibitors [17,18,19]. Here, RET is linked to non-small cell lung carcinoma.